{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:22:17Z","timestamp":1791400937575,"version":"4.3.3"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA168512"],"award-info":[{"award-number":["U54CA168512"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CP130058"],"award-info":[{"award-number":["CP130058"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019194","name":"Iterion Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019194","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002800","name":"Desmoid Tumor Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002800","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Mutation in the <jats:italic>CTNNB1<\/jats:italic> gene, leading to a deregulation of the WTN\/\u03b2-catenin pathway, is a common feature of desmoid tumors (DTs). Many \u03b2-catenin inhibitors have recently been tested in clinical studies; however, BC2059 (also referred as Tegavivint), a selective inhibitor of nuclear \u03b2-catenin that works through binding TBL-1, is the only one being evaluated in a clinical study, specifically for treatment of desmoid tumor patients. Preclinical studies on BC2059 have shown activity in multiple myeloma, acute myeloid leukemia and osteosarcoma. Our preclinical studies provide data on the efficacy of BC2059 in desmoid cell lines, which could help provide insight regarding antitumor activity of this therapy in desmoid tumor patients. <jats:italic>In vitro<\/jats:italic> activity of BC2059 was evaluated using desmoid tumor cell lines. <jats:italic>Ex vivo<\/jats:italic> activity of BC2059 was assessed using an explant tissue culture model. Pharmacological inhibition of the nuclear \u03b2-catenin activity using BC2059 markedly inhibited cell viability, migration and invasion of mutated DT cells, but with lower effect on wild-type DTs. The decrease in cell viability of mutated DT cells caused by BC2059 was due to apoptosis. Treatment with BC2059 led to a reduction of \u03b2-catenin-associated TBL1 in all mutated DT cells, resulting in a reduction of nuclear \u03b2-catenin. mRNA and protein levels of <jats:italic>AXIN2<\/jats:italic>, a \u03b2-catenin target gene, were also found to be downregulated after BC2059 treatment. Taken together, our results demonstrate that nuclear \u03b2-catenin inhibition using BC2059 may be a novel therapeutic strategy for desmoid tumor treatment, especially in patients with <jats:italic>CTNNB1<\/jats:italic> mutation.<\/jats:p>","DOI":"10.1371\/journal.pone.0276047","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T17:54:03Z","timestamp":1665770043000},"page":"e0276047","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Preclinical efficacy of the Wnt\/\u03b2-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3476-8179","authenticated-orcid":true,"given":"Danielle Almeida","family":"Braggio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Costas C. de Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeba","family":"Zewdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Batte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Welliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-7101","authenticated-orcid":true,"given":"Stephen K.","family":"Horrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Strohecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael E.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"4","key":"pone.0276047.ref001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/era.09.9","article-title":"Desmoid tumors: need for an individualized approach.","volume":"9","author":"E. de Bree","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"pone.0276047.ref002","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2017.75.8482","article-title":"Locally Aggressive Connective Tissue Tumors","volume":"36","author":"M. M. Gounder","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"pone.0276047.ref003","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1200\/JCO.2017.35.15_suppl.11022","article-title":"Prospective development of a patient reported outcomes (PRO) tool in desmoid tumors: A novel clinical trial endpoint","volume":"35","author":"J. Paty","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"pone.0276047.ref004","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2353\/ajpath.2008.080475","article-title":"Specific Mutations in the \u03b2-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors","volume":"173","author":"A. J. F. F. Lazar","year":"2008","journal-title":"Am J Pathol"},{"issue":"5","key":"pone.0276047.ref005","doi-asserted-by":"crossref","first-page":"a008052","DOI":"10.1101\/cshperspect.a008052","article-title":"Wnt Signaling in Cancer","volume":"4","author":"P. Polakis","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"pone.0276047.ref006","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2133.2001.04336.x","article-title":"Loss of beta-catenin expression associated with disease progression in malignant melanoma.","volume":"145","author":"T. Kageshita","year":"2001","journal-title":"Br J Dermatol"},{"issue":"6","key":"pone.0276047.ref007","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2353\/ajpath.2010.091125","article-title":"Wnt\/\u03b2-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome","volume":"176","author":"A. I. Khramtsov","year":"2010","journal-title":"Am J Pathol"},{"issue":"7","key":"pone.0276047.ref008","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"K. C. Kurnit","year":"2017","journal-title":"Modern Pathology"},{"issue":"10","key":"pone.0276047.ref009","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mdx323","article-title":"An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)\/Soft Tissue and Bone Sarcoma Group (STBSG)","volume":"28","author":"B. Kasper","year":"2017","journal-title":"Annals of Oncology"},{"issue":"2","key":"pone.0276047.ref010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2014.11.019","article-title":"Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients","volume":"51","author":"C. Colombo","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"pone.0276047.ref011","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1634\/theoncologist.2010-0281","article-title":"Desmoid tumors: clinical features and treatment options for advanced disease.","volume":"16","author":"B. Kasper","year":"2011","journal-title":"Oncologist"},{"key":"pone.0276047.ref012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-41906-0_1","volume-title":"Management of Soft Tissue Sarcoma","author":"M. F. Brennan","year":"2016"},{"issue":"5","key":"pone.0276047.ref013","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y","article-title":"Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis","volume":"92","author":"A. Azzarelli","year":"2001","journal-title":"Cancer"},{"issue":"12","key":"pone.0276047.ref014","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/1097-0142(19871215)60:12<2863::AID-CNCR2820601202>3.0.CO;2-I","article-title":"The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis.","volume":"60","author":"W. A. Klein","year":"1987","journal-title":"Cancer"},{"issue":"5","key":"pone.0276047.ref015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0360-3016(98)00285-5","article-title":"Radiation therapy in the management of desmoid tumors.","volume":"42","author":"M. T. Ballo","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"pone.0276047.ref016","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1200\/JCO.2009.25.5950","article-title":"Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot Study","volume":"28","author":"Y. Nishida","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"pone.0276047.ref017","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for Advanced and Refractory Desmoid Tumors","volume":"379","author":"M. M. Gounder","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"pone.0276047.ref018","doi-asserted-by":"crossref","DOI":"10.1002\/med.21787","article-title":"Direct targeting of \u03b2 \u2010catenin in the Wnt signaling pathway: Current progress and perspectives","volume":"41","author":"Z. Wang","year":"2021","journal-title":"Med Res Rev"},{"issue":"1","key":"pone.0276047.ref019","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Y. Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"pone.0276047.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.07.007","article-title":"Advances in targeting the WNT\/\u03b2-catenin signaling pathway in cancer","volume":"27","author":"A. Chatterjee","year":"2022","journal-title":"Drug Discov Today"},{"key":"pone.0276047.ref021","article-title":"Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059\u2014Full Text View\u2014ClinicalTrials.gov"},{"issue":"6","key":"pone.0276047.ref022","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/leu.2014.340","article-title":"Pre-clinical efficacy of combined therapy with novel \u03b2-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.","volume":"29","author":"W. Fiskus","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"pone.0276047.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(04)00133-3","article-title":"A Corepressor\/Coactivator Exchange Complex Required for Transcriptional Activation by Nuclear Receptors and Other Regulated Transcription Factors","volume":"116","author":"V. Perissi","year":"2004","journal-title":"Cell"},{"issue":"2","key":"pone.0276047.ref024","article-title":"TBL1\u2013TBLR1 and \u03b2-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis","volume":"10","author":"J. Li","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"18","key":"pone.0276047.ref025","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M109.049411","article-title":"Direct Ubiquitination of \u03b2-Catenin by Siah-1 and Regulation by the Exchange Factor TBL1","volume":"285","author":"Y. N. Dimitrova","year":"2010","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"pone.0276047.ref026","article-title":"Siah-1 Mediates a Novel \u03b2-Catenin Degradation Pathway Linking p53 to the Adenomatous Polyposis Coli Protein","volume":"7","author":"J. Liu","year":"2001","journal-title":"Mol Cell"},{"issue":"22","key":"pone.0276047.ref027","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1002\/cncr.29564","article-title":"Targeting the N otch pathway: A potential therapeutic approach for desmoid tumors","volume":"121","author":"H. Shang","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"pone.0276047.ref028","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/0008-5472.CAN-07-6268","article-title":"Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha.","volume":"68","author":"Q.-S. Zhu","year":"2008","journal-title":"Cancer Res"},{"key":"pone.0276047.ref029","article-title":"Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors","author":"D. Braggio","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"pone.0276047.ref030","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-16-0624","article-title":"\u03b2-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma","volume":"16","author":"I. Savvidou","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"pone.0276047.ref031","article-title":"Clinical Activity of the \u03b3-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)","author":"S. Kummar","year":"2017","journal-title":"J Clin Oncol"},{"key":"pone.0276047.ref032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2017.02.001","article-title":"Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)","volume":"76","author":"B. Kasper","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"pone.0276047.ref033","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1158\/1078-0432.CCR-10-3322","article-title":"Activity of Sorafenib against desmoid tumor\/deep fibromatosis.","volume":"17","author":"M. M. Gounder","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pone.0276047.ref034","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer.","volume":"36","author":"T. Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"4","key":"pone.0276047.ref035","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/1535-7163.MCT-13-0555","article-title":"Effect of Niclosamide on Basal-like Breast Cancers","volume":"13","author":"A. I. Londono-Joshi","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"pone.0276047.ref036","doi-asserted-by":"crossref","first-page":"e102535","DOI":"10.1371\/journal.pone.0102535","article-title":"Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy via Suppressing Wnt\/\u03b2-Catenin Signaling Pathway","volume":"9","author":"Y. Fu","year":"2014","journal-title":"PLoS One"},{"issue":"21","key":"pone.0276047.ref037","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1158\/1078-0432.CCR-09-0262","article-title":"Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na\/I Symporter","volume":"15","author":"I. Peerlinck","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"6938","key":"pone.0276047.ref038","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature01593","article-title":"A role for Wnt signalling in self-renewal of haematopoietic stem cells","volume":"423","author":"T. Reya","year":"2003","journal-title":"Nature"},{"issue":"6","key":"pone.0276047.ref039","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1083\/jcb.127.6.2061","article-title":"E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton.","volume":"127","author":"J. H\u00fclsken","year":"1994","journal-title":"J Cell Biol"},{"issue":"53","key":"pone.0276047.ref040","doi-asserted-by":"crossref","first-page":"90608","DOI":"10.18632\/oncotarget.21293","article-title":"Molecular insights into desmoid tumors.","volume":"8","author":"N. Bui","year":"2017","journal-title":"Oncotarget"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T17:54:46Z","timestamp":1665770086000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276047"}},"subtitle":[],"editor":[{"given":"Dominique","family":"Heymann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0276047","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}